Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norursodeoxycholic acid vs placebo in primary sclerosing cholangitis
2023-510200-42-00Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of norursodeoxycholic acid in Primary Sclerosing Cholangitis (PSC) (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Partial normalization of serum alkaline phosphatase and no worsening of disease stage (Ludwig stage). Started Oct 2024; status: completed.
02
Drugs
norursodeoxycholic acid
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2023-510200-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510200-42-00.